# OnCo record dabrafenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:Drug ;
onco:kind "drug" ;
schema:identifier "dabrafenib" ;
schema:name "Dabrafenib"@en ;
schema:description "Dabrafenib (Tafinlar) is a capsule that switches off the faulty BRAF protein driving some melanomas, lung, thyroid and other cancers. It is almost always paired with trametinib."@en ;
schema:url ;
schema:dateModified "2026-09-10"^^xsd:date ;
schema:sameAs ;
schema:citation , , ;
onco:status "approved" ;
onco:tag "nci-list" ;
onco:modality "Small-molecule BRAF kinase inhibitor" ;
schema:alternateName "Tafinlar" ;
onco:approval "US 2013: BRAF V600E unresectable or metastatic melanoma (single agent)", "US 2014: With trametinib: BRAF V600E/K metastatic melanoma; later adjuvant melanoma, BRAF V600E NSCLC, anaplastic thyroid cancer, tumour-agnostic solid tumours and paediatric low-grade glioma", "EU 2013: BRAF V600 melanoma; later NSCLC and adjuvant melanoma with trametinib" ;
onco:acceleratedApproval "US 2014-01-09: In combination with trametinib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test", "US 2022-06-22: In combination with trametinib for adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. *" ;
onco:acceleratedApprovalConfirmed "US 2015-11-20: In combination with trametinib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test" ;
onco:related , ;
onco:cancers , , , , , , , , , ;
onco:technologies ;
onco:targets ;
onco:companies ;
onco:pathways ;
onco:trials , , .